Strain Profile
· NCBI Strain Taxon
440496
NCBI Taxonomy's node for this specific strain. A different identifier from the culture-collection deposit numbers below, which name a physical stock rather than a taxonomic node.
How we classify this →
Save
Lactobacillus crispatus CTV-05
◐
Food-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Lactobacillus crispatus CTV-05, marketed as LACTIN-V, is a vaginally administered live biotherapeutic product studied in one of the more extensive clinical development programs among probiotic strains. Multiple phase 2 randomized controlled trials have evaluated its ability to establish and sustain vaginal colonization following antibiotic treatment for bacterial vaginosis, examining colonization in relation to recurrence of the condition. Research has also examined its relationship to genital tract inflammation and, in high-risk populations, susceptibility to sexually transmitted infections. CTV-05 is a vaginal, not oral, formulation, and the strain's behavior via oral delivery has not been established. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 29 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 23 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
32 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2026
RCT
2025
RCT
2025
OBSERVATIONAL
2025
RCT
2025
RCT
2024
RCT
2024
RCT
2024
OBSERVATIONAL
2023
RCT
2022
RCT
2020
REVIEW
2020
RCT
2020
RCT
2019
IN_VITRO
2018
RCT
2012
RCT
2011
RCT
2010
RCT
2009
RCT
2009
RCT
Browse all 32 papers →
Vaginal microbe-binding antibody interactions with a Lactobacillus crispatus live biotherapeutic following treatment for bacterial vaginosis
· Microbiology Spectrum
Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial
· The Lancet Microbe
StrainFacts accurately quantifies both endogenous and live biotherapeutic product strain abundances in simulated and clinical vaginal microbiota samples
· bioRxiv (Cold Spring Harbor Laboratory)
Microbiota effects and predictors of Lactobacillus crispatu s colonization after treatment with a vaginal live biotherapeutic: results from a randomized, double-blinded, placebo-controlled trial
· medRxiv
Acceptability of the live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) among young women at high risk of HIV acquisition in South Africa: data from the phase 2 placebo-controlled trial
· Frontiers in Reproductive Health
Vaginal Lactobacillus crispatus persistence following application of a live biotherapeutic product: colonization phenotypes and genital immune impact
· Microbiome
Response to Antibiotic Treatment of Bacterial Vaginosis Predicts the Effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the Prevention of Recurrent Disease
· Sexually Transmitted Diseases
Targeting the Vaginal Microbiota to Reduce HIV Susceptibility
· TSpace
Response to antibiotic treatment of bacterial vaginosis predicts the effectiveness of LACTIN-V (Lactobacillus crispatus CTV-05) in the prevention of recurrent disease
· medRxiv
Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial
· The Lancet Microbe
Connecting the Dots: Translating the Vaginal Microbiome Into a Drug
· The Journal of Infectious Diseases
Effect of clindamycin and a live biotherapeutic on the reproductive outcomes of IVF patients with abnormal vaginal microbiota: protocol for a double-blind, placebo-controlled multicentre trial
· BMJ Open
Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis
· New England Journal of Medicine
Diverse Expression of Antimicrobial Activities Against Bacterial Vaginosis and Urinary Tract Infection Pathogens by Cervicovaginal Microbiota Strains of Lactobacillus gasseri and Lactobacillus crispatus
· Frontiers in Microbiology
126. Robust and Persistent Vaginal Colonization with LACTIN-V Vaginal Lactobacillus crispatus Probiotic in a Double-Blind, Placebo-Controlled (DBPC) Phase 2b Trial to Prevent Recurrent UTI (rUTI)
· Open Forum Infectious Diseases
Effects of Bacterial Vaginosis Associated Bacteria, Endogenous Lactobacillus and Sociodemographic Factors on Vaginal Colonization with the Probiotic Lactobacillus crispatus CTV-05: A Study of the Intervention Cohort in a Phase IIA Clinical Trial of LACTIN
Effects of Bacterial Vaginosis Associated Bacteria, Endogenous Lactobacillus and Sociodemographic Factors on Vaginal Colonization with the Probiotic Lactobacillus crispatus CTV-05: A Study of the Intervention Cohort in a Phase IІA Clinical Trial of LACTIN
· Abstracts of postgraduate thesis
Effects of Bacterial Vaginosis-Associated Bacteria and Sexual Intercourse on Vaginal Colonization With the Probiotic Lactobacillus crispatus CTV-05
· Sexually Transmitted Diseases
Phase 2a Study Assessing Colonization Efficiency, Safety, and Acceptability of Lactobacillus crispatus CTV-05 in Women With Bacterial Vaginosis
· Sexually Transmitted Diseases
Phase 1 Dose-Ranging Safety Trial of Lactobacillus crispatus CTV-05 for the Prevention of Bacterial Vaginosis
· Sexually Transmitted Diseases
Vaginal Colonization by Probiotic Lactobacillus crispatus CTV‐05 Is Decreased by Sexual Activity and Endogenous Lactobacilli
· The Journal of Infectious Diseases
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
PMID 42678149 →Vaginal microbe-binding antibody interactions with a Lactobacillus crispatus live biotherapeutic following treatment for bacterial vaginosis· Microbiology Spectrum · 2026
-
[2]
PMID 40901072 →Microbiota effects and predictors of Lactobacillus crispatu s colonization after treatment with a vaginal live biotherapeutic: results from a randomized, double-blinded, placebo-controlled trial· medRxiv · 2025
-
[3]
PMID 40194532 →Effect of the vaginal live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) on vaginal microbiota and genital tract inflammation among women at high risk of HIV acquisition in South Africa: a phase 2, randomised, placebo-controlled trial· The Lancet Microbe · 2025
-
[4]
PMID 40206350 →Acceptability of the live biotherapeutic LACTIN-V (Lactobacillus crispatus CTV-05) among young women at high risk of HIV acquisition in South Africa: data from the phase 2 placebo-controlled trial· Frontiers in Reproductive Health · 2025
-
[5]
PMID 38907268 →Vaginal Lactobacillus crispatus persistence following application of a live biotherapeutic product: colonization phenotypes and genital immune impact· Microbiome · 2024
-
[6]
PMID 35659905 →Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial· The Lancet Microbe · 2022
-
[7]
PMID 32402161 →Randomized Trial of Lactin-V to Prevent Recurrence of Bacterial Vaginosis· New England Journal of Medicine · 2020
-
[8]
PMID 21992977 →Effects of Bacterial Vaginosis-Associated Bacteria and Sexual Intercourse on Vaginal Colonization With the Probiotic Lactobacillus crispatus CTV-05· Sexually Transmitted Diseases · 2011
-
[9]
PMID 19543144 →Phase 1 Dose-Ranging Safety Trial of Lactobacillus crispatus CTV-05 for the Prevention of Bacterial Vaginosis· Sexually Transmitted Diseases · 2009
-
[10]
PMID 18288237 →Phase I Trial of a Lactobacillus crispatus Vaginal Suppository for Prevention of Recurrent Urinary Tract Infection in Women· Infectious Diseases in Obstetrics and Gynecology · 2007